NASDAQ:SXTP 60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis $1.36 -0.08 (-5.56%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.35▼$1.5150-Day Range$0.09▼$1.9252-Week Range$1.03▼$18.36Volume93,756 shsAverage Volume1.03 million shsMarket Capitalization$16.60 millionP/E RatioN/ADividend YieldN/APrice Target$2.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get 60 Degrees Pharmaceuticals alerts: Email Address 60 Degrees Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside76.5% Upside$2.40 Price TargetShort InterestHealthy6.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.43) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 stars 3.3 Analyst's Opinion Consensus Rating60 Degrees Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst Coverage60 Degrees Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about 60 Degrees Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.89% of the float of 60 Degrees Pharmaceuticals has been sold short.Short Interest Ratio / Days to Cover60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 60 Degrees Pharmaceuticals has recently decreased by 78.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield60 Degrees Pharmaceuticals does not currently pay a dividend.Dividend Growth60 Degrees Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SXTP. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for 60 Degrees Pharmaceuticals this week, compared to 1 article on an average week.Search Interest11 people have searched for SXTP on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 60 Degrees Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.27% of the stock of 60 Degrees Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.Read more about 60 Degrees Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($5.43) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 60 Degrees Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 60 Degrees Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about 60 Degrees Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.Read More SXTP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SXTP Stock News HeadlinesSeptember 7 at 10:51 AM | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 4 at 8:00 AM | globenewswire.com60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsAugust 18, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses ExpectationsAugust 14, 2024 | globenewswire.com60 Degrees Pharmaceuticals Announces Second Quarter 2024 ResultsAugust 12, 2024 | msn.comShould You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?August 12, 2024 | investorplace.comWhy Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 12, 2024 | msn.comUpcoming Stock Splits This Week (August 12 to August 16) – Stay InvestedAugust 12, 2024 | globenewswire.com60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb StudyAugust 6, 2024 | finanznachrichten.de60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade SupportAugust 6, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock SplitJuly 25, 2024 | finanznachrichten.deSixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade SupportJuly 25, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportJuly 20, 2024 | msn.comDow Tumbles Over 100 Points; American Express Earnings Beat ViewsJuly 20, 2024 | finance.yahoo.com(XS2531438351.SG)July 20, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudySee More Headlines Receive SXTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SXTP CUSIPN/A CIK1946563 Web60degreespharma.com Phone202-327-5422FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$2.40 High Stock Price Target$2.40 Low Stock Price Target$2.40 Potential Upside/Downside+76.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,770,000.00 Net MarginsN/A Pretax Margin-2,346.38% Return on EquityN/A Return on Assets-98.31% Debt Debt-to-Equity RatioN/A Current Ratio3.09 Quick Ratio2.74 Sales & Book Value Annual Sales$418,304.00 Price / Sales39.68 Cash FlowN/A Price / Cash FlowN/A Book Value($3.90) per share Price / Book-0.35Miscellaneous Outstanding Shares12,206,000Free Float10,952,000Market Cap$16.60 million OptionableNot Optionable Beta4.61 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Geoffrey Stuart Dow (Age 50)Chairman, CEO & President Comp: $125.56kMr. Tyrone Miller (Age 49)CFO & Treasurer Comp: $135.63kDr. Bryan Smith (Age 58)Chief Medical Officer Ms. Kristen Landon (Age 57)Chief Commercial Officer Ms. Jennifer HerzDirectorKey CompetitorsAffimedNASDAQ:AFMDKronos BioNASDAQ:KRONHookipa PharmaNASDAQ:HOOKAllakosNASDAQ:ALLKPortage BiotechNASDAQ:PRTGView All CompetitorsInstitutional OwnershipCentral Bank & Trust Co.Sold 101,000 shares on 7/19/2024Ownership: 1.368%View All Institutional Transactions SXTP Stock Analysis - Frequently Asked Questions How have SXTP shares performed this year? 60 Degrees Pharmaceuticals' stock was trading at $1.02 at the start of the year. Since then, SXTP shares have increased by 33.3% and is now trading at $1.36. View the best growth stocks for 2024 here. How were 60 Degrees Pharmaceuticals' earnings last quarter? 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($4.23) earnings per share for the quarter, missing the consensus estimate of ($2.79) by $1.44. The company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.11 million. When did 60 Degrees Pharmaceuticals' stock split? 60 Degrees Pharmaceuticals's stock split on Saturday, January 1st 2000. The 12-1 split was announced on Saturday, January 1st 2000. The newly minted shares were distributed to shareholders after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the split would have 1,200 shares after the split. When did 60 Degrees Pharmaceuticals IPO? 60 Degrees Pharmaceuticals (SXTP) raised $7 million in an initial public offering (IPO) on Wednesday, July 12th 2023. The company issued 1,400,000 shares at a price of $5.30 per share. WallachBeth Capital LLC acted as the underwriter for the IPO. Who are 60 Degrees Pharmaceuticals' major shareholders? Top institutional shareholders of 60 Degrees Pharmaceuticals include Central Bank & Trust Co. (1.37%). How do I buy shares of 60 Degrees Pharmaceuticals? Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SXTP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
